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Summary
Using longitudinal data from a cohort of 1349 participants in the
Framingham Heart Study, we show that as early as 28–38 years of
age, almost 10% of variation in future lifespan can be predicted
from simple clinical parameters. Specifically, we found diastolic
and systolic blood pressure, blood glucose, weight, and body
mass index (BMI) to be relevant to lifespan. These and similar
parameters have been well-characterized as risk factors in the
relatively narrow context of cardiovascular disease and mortality
in middle to old age. In contrast, we demonstrate here that such
measures can be used to predict all-cause mortality from mid-
adulthood onward. Further, we find that different clinical mea-
surements are predictive of lifespan in different age regimes.
Specifically, blood pressure and BMI are predictive of all-cause
mortality from ages 35 to 60, while blood glucose is predictive
from ages 57 to 73. Moreover, we find that several of these
parameters are best considered as measures of a rate of ‘damage
accrual’, such that total historical exposure, rather than current
measurement values, is the most relevant risk factor (as with
pack-years of cigarette smoking). In short, we show that simple
physiological measurements have broader lifespan-predictive
value than indicated by previous work and that incorporating
information from multiple time points can significantly increase
that predictive capacity. In general, our results apply equally to
both men and women, although some differences exist.
Key words: aging; biodemography; cumulative risk;
mortality; physiology; risk prediction.
Introduction
Aging is a complex biological process with multiple contributing genetic
pathways (Kenyon et al., 1993; Lakowski & Hekimi, 1996; Hansen et al.,
2007; Lunetta et al., 2007; Pan et al., 2007; Willcox et al., 2008; Li
et al., 2009; Imai & Guarente, 2014; Satoh & Imai, 2014), significant
variation among even closely related organisms (Jones et al., 2014), and
an ongoing debate about its root causes and origin (Kirkwood, 2005). At
its core, however, aging is simply the statistical phenomenon of an
increased probability of death over time. In addition, mortality risk does
not increase at equal rates at all ages (Vaupel et al., 1998). Further,
aging can vary significantly for different individuals at the same age. As a
result, an individual’s chronological age is a limited predictor of their
actual mortality risk.
In order to develop improved prognostic capability for mortality,
demographers have sought to identify biomarkers of aging, functionally
defined as a biological parameter of an organism that either can better
predict functional capability or mortality risk than chronological age
(Baker & Sprott, 1988). This is motivated by an array of valuable
applications, including improved actuarial modeling, biological investi-
gations of the mechanisms of aging and therapeutics to slow its
progress, and the clinical ability to better target interventions to at-risk
patients.
Driven by these goals, researchers in the 1970s and 1980s proposed a
large number of candidate biomarkers of aging (Baker, 1975; Ludwig &
Smoke, 1980; Ingram & Reynolds, 1986). Although these studies
identified several putative biomarkers, many of the published multivari-
able composite scores were overfit—that is, overly tuned to a very
specific dataset. Consequently, these composite scores did not have
broad applicability, and later studies failed to validate the original
findings (Baker & Sprott, 1988; Costa & McCrae, 1988; Dean & Morgan,
1988; Ingram, 1988; Wilson, 1988).
As a result, much subsequent work has focused on predicting specific
disease processes instead of all-cause mortality (Cook et al., 1995; Vasan
et al., 2001; Sesso et al., 2008). Many physiological parameters, such as
blood pressure (Kannel, 1996) and body mass index (BMI) (Eckel et al.,
1998), have been well-characterized as risk factors for cardiovascular
disease and other specific morbidities. In general, these studies have
focused on middle-aged individuals and have emphasized risk over a
limited term, often just 5- or 10-year periods (e.g., Assmann et al.,
2002). In addition, most of the work on both general biomarkers of
aging and specific risk factors has been limited to the analysis of data
from single time points.
More recently, Yashin and colleagues have sought to use longitudinal
data to gain insight into the overall aging process and the relationship
between physiological change over time and mortality risk (e.g., Yashin
et al., 2013). In particular, modeling physiological change as a dynamic
system allowed mortality risk to be successfully modeled as a function of
the difference between an individuals’ current physiological state and
the ideal state for an individual of that age (Yashin et al., 2007; Arbeev
et al., 2011). Related analyses classified individuals’ likely lifespans
according to trajectories of physiological indices (Yashin et al., 2006,
2010). Further, a landmark series of studies of the accumulation of age-
related functional deficits in individuals over time identified a snowball
effect where individuals with physiological deficits are more likely to
accumulate further deficits over time and are exponentially more likely to
die (Mitnitski et al., 2005, 2006). Taken together, these studies indicate
that the trajectory of an individuals’ physiological state over time
provides a rich context for understanding future mortality risk.
We therefore set out to address two very simple questions about
lifespan prediction from longitudinal data. First, given an individuals’
history of physiological measurements (blood pressure, height, weight,
and similar), how early in life is there any indication of that individuals’
ultimate lifespan? A very recent investigation showed that that aging is
Correspondence
Zachary Pincus, Washington University School of Medicine, CB 8232, 660 South
Euclid Avenue, St. Louis, MO 63110, USA. Tel.: +1-314-747-5520; fax: +1-314-
362-7588; e-mail: zpincus@wustl.edu
Accepted for publication 8 September 2015
ª 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
39
Aging Cell (2016) 15, pp39–48 Doi: 10.1111/acel.12408
Ag
in
g 
Ce
ll
indeed detectable even in young adults (Belsky et al., 2015). Specifically,
these investigators found that young adults who showed signs of
accelerated physiological aging also experienced greater functional
impairment. We now ask whether such early-life aging has detectable
impacts on eventual survival decades hence.
Second, this work seeks to determine whether data from multiple
time points can be aggregated in any way to provide a clearer estimate
of future lifespan? Many of the models presented in previous work (e.g.
Mitnitski et al., 2006; Yashin et al., 2007; Arbeev et al., 2011) use
longitudinal data, but estimate mortality risk at a particular time only
from measurements made at that time. This effectively assumes that
mortality risks are a memory-free Markov process. In this work, we test
this assumption and determine whether physiological history is helpful in
lifespan prediction.
Our investigation of longer term biomarkers of longevity was made
possible by the continued progression of the Framingham Heart Study
(FHS). With its large cohort, consistent longitudinal measurements of
basic physiology, and excellent level of follow-up in terms of rate and
length, the FHS offers a unique opportunity to investigate the contri-
butions of biomarkers from very young ages, as well as the evolution of
biomarker effectiveness throughout the aging process. The FHS popu-
lation also allows us to focus on a single longitudinal cohort of
individuals, avoiding the possible confounding effects of using additional
cross-sectional data. In this work, we use the Framingham data to
understand the proportion of variation in all-cause mortality that can be
predicted from basic clinical measurements. We study these effects from
early- to mid-adulthood, and examine how they evolve as a result of the
aging process (Table 1).
Results
To understand the mortality-predictive ability of various physiological
biomarkers, we began by selecting a well-defined and homogeneous
cohort of individuals to analyze. In order to study the effect of
biomarkers on mortality risk at a young age and the effects of
incorporating past measurements into predictive models, we chose to
focus on the youngest individuals in the original cohort of the
Framingham Heart Study. The data from these individuals are both the
most extensive and begin earliest in life. Moreover, this cohort, aged 28–
38 years at the first Framingham exam, shares a birth decade, limiting
the opportunity for confounding effects due to cultural and medical
changes over time.
Of the hundreds of measurements made by the Framingham
investigators, we chose to focus on basic parameters that were not
indicators for any specific pathology and which had a wide dynamic
range of variation (e.g., not binary variables such as whether a specific
type of cardiac arrhythmia was detected on physical exam). After
eliminating parameters that were not consistently measured across the
first 28 clinical exams (over 50 years) of the study, we obtained a panel
containing weight, height, systolic and diastolic blood pressure, BMI, and
blood glucose.
Amount of mortality predictable from physiology
In order to determine the fraction of variability in lifespan that can be
predicted from the first exam, we employed multiple linear regression to
assign weights to our six selected measurements. This allowed us to
combine the six variables into a single composite ‘risk score’ and to
assess its relationship with mortality (measured in days of survival after
the first clinical exam). The relationship between predicted lifespan and
results is shown in Fig. 1 (at the first clinical exam, when our cohort of
participants is 28–38 years old). Overall, approximately 10% of variation
in ultimate lifespan is predictable using a simple linear regression on six
basic clinical parameters (p = 8.52 9 1032).
In this type of analysis, weights for each measured parameter are
chosen based on the known survival time of each individual. With
sufficiently many parameters, models constructed in this fashion can
become ‘overfit’ and not generalize well to future data. In this case, we
have few parameter weights (seven: six measurements plus a constant
offset) compared to the size of the data, and thus, the model is unlikely
to be overfit. To demonstrate this directly, we estimated the ability of the
model to generalize to future data using five-fold cross-validation, in
which different subsets of the data were used to fit the weights vs.
evaluate the goodness of that fit. This generated a Pearson r2 of 0.085,
suggesting that these results are indeed not overfit.
Thus, even relatively early in adulthood, a modest but meaningful
fraction of future lifespan is already predictable. Further, the lack of
sharp demarcations on the scatterplot indicates that this correlation is
not driven exclusively by individuals with overt pathologies. Rather, the
effect is graded, and is spread over much of the dynamic range that
exists for both the clinical measurements and the length of known
survival.
Next, we asked how the proportion of predictable mortality from
single time points changes as the cohort ages. Figure 2 (left) shows the
correlation between the measured parameters and mortality throughout
the aging process, for the subcohort of our original population still alive
Table 1 Summary statistics of the changing demographics of the surviving cohort
over time
Living
subcohort
size
Mean age
(years)
%
Males
%
Females
Number
of males
Number
of females
Exam 01 1349 34.5  2.2 47 53 631 718
Exam 02 1329 36.6  2.2 47 53 620 709
Exam 03 1311 38.5  2.2 47 53 611 700
Exam 04 1301 40.5  2.2 46 54 604 697
Exam 05 1285 42.5  2.2 46 54 597 688
Exam 06 1270 44.5  2.2 46 54 587 683
Exam 07 1256 46.5  2.2 46 54 582 674
Exam 08 1236 47.9  2.2 46 54 573 663
Exam 09 1216 49.9  2.2 46 54 562 654
Exam 10 1189 52.0  2.2 46 54 547 642
Exam 11 1162 53.8  2.2 46 54 535 627
Exam 12 1136 56.0  2.2 46 54 527 609
Exam 13 1108 58.0  2.2 46 54 512 596
Exam 14 1071 60.0  2.2 45 55 487 584
Exam 15 1031 61.9  2.2 45 55 460 571
Exam 16 987 63.9  2.2 44 56 435 552
Exam 17 956 65.9  2.2 44 56 416 540
Exam 18 893 68.1  2.2 43 57 384 509
Exam 19 836 70.1  2.2 42 58 351 485
Exam 20 789 72.2  2.2 41 59 322 467
Exam 21 724 74.1  2.2 39 61 282 442
Exam 22 646 76.0  2.2 39 61 251 395
Exam 23 580 77.8  2.2 37 63 217 363
Exam 24 488 79.9  2.2 36 64 177 311
Exam 25 455 81.8  2.2 35 65 159 296
Exam 26 376 83.8  2.2 32 68 122 254
Exam 27 301 85.5  2.1 31 69 94 207
Exam 28 236 87.2  2.0 32 68 76 160
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at each time point, stratified for gender. (Note that the trends in these
correlations thus include both the effects of age and of survivorship
bias.) The three different traces represent three approaches to
constructing a composite ‘risk score’ from the clinical data.
First, we used the weights that were computed to be optimal for
predicting lifespan at exam 1, when the mean age of the cohort was
34.5 years (Fig. 1, bottom). The decrease in the predictive ability of this
score over time suggests that the risk factors that are important in early
life become less relevant in middle age. To illustrate this more explicitly,
we then calculated the set of weights that most optimally predict future
lifespan at exam 18, when the mean age was 68.1 years. As expected,
the ‘exam 18’ trace is a worse predictor than the ‘exam 1’ trace early on,
but is more effective at later time points. We next used regression to
determine the optimal weighting of the six parameters at each
Framingham study exam (the ‘focal exam’) independently. This provides
an upper bound on fraction of lifespan predictable in a linear fashion
from these basic measurements over time. (Nonlinear regression models
with more free parameters may well be able to predict more about
future lifespan; we excluded these from our analysis as a guard against
overfitting and multiple hypothesis testing.) Of note is the gradual
decline in our ability to predict mortality after roughly age 60. This
suggests that the physiological parameters analyzed are able to capture
relevant differences between those who die relatively early and those
who die later, but not the variation among particularly longer lived
individuals.
To put our findings into the context of previously developed clinical
risk scores, Fig. 2 (center) compares the lifespan-predictive ability of the
well-known Framingham Risk Score (Wilson et al., 1998; Lloyd-Jones
et al., 2004) and Pooled Cohort Score (Goff et al., 2014) with our ‘focal
exam’ estimates. These clinical scores were designed specifically to assess
cardiovascular risk in a 5- to 10-year timeframe, using some of the
parameters we examined as well as smoking status, blood cholesterol,
and age. Despite this narrow focus, however, both scores are able to
predict a significant proportion of variation in all-cause mortality over
50+ years of follow-up. Indeed, their predictive value remains valid even
at the earliest clinical exam, when the average age of participants is
34.5 years. This demonstrates a surprising robustness of the lifespan-
predictive signal in these data: even risk scores such as these, which were
not specifically tuned to the task, are effective biomarkers of aging.
Next, Fig. 3 illustrates how the individual measurements’ (from Fig. 1)
correlations with future lifespan change over time. As expected, the
predictive ability of most of the parameters under investigation declines
as the overall predictable mortality (measured by the focal exam trace
from Fig. 2) declines. This trend is most strongly illustrated by the three
blood pressure variables, systolic, diastolic and pulse pressure, which are
highly predictive of lifespan from ages 35 to 60 and increasingly less
predictive thereafter. On the other hand, blood glucose is a striking
exception. Up to age 70, as all other significant predictors’ correlations
are declining, the correlation of blood glucose with all-cause mortality
rises consistently, achieving its highest values from the ages of 57–73.
Overall, it appears that blood pressure and BMI are predictive of all-cause
mortality early in life (ages 35–60, with pulse pressure interestingly being
a stronger predictor in late life than systolic and diastolic blood pressure),
while blood glucose is more meaningful in middle age (ages 57–73). This
reinforces the evidence from Fig. 2 that the mortality-predictive ability of
our clinical variables changes during different phases of life.
Incorporating physiological history into mortality prediction
As the Framingham data provide measurements of the same physiolog-
ical parameters at different ages for each individual, we next investigated
whether and how trends in these measures over time are predictive of
future lifespan (Fig. 4). The simplest possibility is that a particular
measurement directly reflects the current state of health of an individual
at that moment (central panel in Fig. 4). In this case, the previous values
of that measurement are redundant/irrelevant. Alternately, there may be
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Fig. 1 In early- to mid-adulthood
(participants aged 28–38), 9.7% of
variation in future lifespan can be predicted
from a weighted combination of systolic
and diastolic blood pressure, blood glucose,
height, weight, and body mass index. (top)
Scatter plot of predicted lifespan from
clinical measurements and actual future
survival. Note that the composite predictor
does not simply measure overt pathology,
but has a graded response across the full
dynamic range of lifespans. (bottom)
Summary information for the six
components of the composite predictor,
along with age for comparison. At the first
clinical exam, systolic pressure and diastolic
blood pressure are the strongest drivers of
predictions of all-cause mortality, as shown
by the r2 for the in the single-variable
correlations with future lifespan.
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cases where the precise value of a clinical measurement itself is not
particularly important for prognosis, but its rate of change with time is
more reflective of future health (illustrated by the slope of the tangent
line in the left panel in Fig. 4). For example, progressive increases in the
size of a skin blemish could indicate a malignancy, while the actual size
of the blemish itself may be less relevant. Finally, other clinical measures
may directly capture rates of change of health, such that the relevant
information for prognosis is the cumulative change over time (the
integrated ‘area under the curve’, illustrated by the shaded region in the
right panel in Fig. 4). One clear example is an individual’s risk from their
history of smoking. In that case, there is significant evidence that one’s
smoking ‘rate’ (packs per day) is in some sense a rate of decline of health
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Fig. 2 (left) The proportion of lifespan
predictable from various approaches to
constructing composites generally
decreases with age. The trace computed by
re-calculating the regression weights at
each time point independently (‘focal’) sets
an upper bound on the portion of survival
that predictable at each time point. The
‘exam 1’ trace performs well for early
exams, but becomes less relevant at more
advanced ages. Finally, the ‘exam 18’ trace,
created by fitting data from individuals at
clinical exam 18, performs worse than the
‘exam 1’ trace at early time points but
better at later ones. (center) Our ‘focal’
exam score is compared to the Framingham
Heart Score (FHS) and the Pooled Cohort
Equation Risk Score (PCERS), two well-
known cardiovascular risk scores. Strikingly,
the PCERS and FHS seem to behave like the
‘exam 1’ and ‘combined’ traces,
respectively. Note that the FHS and PCERS
are not subject to the ‘upper bound’ set by
the ‘focal’ trace, as they include
information from additional variables (such
as blood cholesterol and age itself) not used
for the ‘focal’ trace calculation. (right) A
survival curve for the overall cohort studied,
illustrating how the size of the surviving
subcohort changes over time.
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and that the true risk is best predicted by total accumulated underlying
damage (typically reported as ‘pack-years’ of smoking), rather than the
current smoking rate.
To see which of these possibilities best fits the observed data, we
computed ‘rates of change’ (i.e., differentiated) and ‘cumulative’ (i.e.,
integrated) versions of our variables and analyzed their correlations with
mortality. We first attempted several formulations of ‘rates of change’:
taking the difference between successive exams; reducing noise by
finding the slope of a line fitted to three exam time points rather than
two; and smoothing the data by averaging multiple adjacent exams
before obtaining pointwise rates of change as above. We found that no
‘rate of change’ formulation was predictive of mortality (data not
shown).
We next focused on the accumulation hypothesis, in which integrat-
ing past values for a given measurement might yield improved predictive
ability. To explore the idea of accumulated risk, we constructed variables
analogous to pack-years for smoking by simply summing past measure-
ments, weighed to account for the uneven timing of the Framingham
exams. If, as hypothesized, a particular variable represents a ‘rate of
change’ of health, then its accumulated history will be more predictive of
mortality than its current single time value. Continuing the example of
smoking, an individual’s accumulated pack-years of smoking should
have a stronger correlation with survival than their current smoking rate.
Further, looking at intermediate amounts of history should yield
intermediate levels of predictive capacity. For example, if we obtain
individuals’ smoking history for only the previous 5 years, that variable’s
correlation with mortality should be greater than the correlation from
the single time measurement, but less than the correlation obtained for
their full lifetime history of smoking. If, on the other hand, integrating
the most recent 5 years or so of history improves predictive abilities but
earlier historical data adds nothing, this may suggest that the ‘integrated
recent history’ may simply be a de-noised estimate of the current
physiological state. While such denoising may be clinically useful, it is not
good evidence that the risk factor truly is cumulative.
For this analysis, we begin with the single time correlation at a
particular exam (the ‘focal exam’), then trace the mortality-predictive
abilities of individual clinical parameters as progressively more years of
history are incorporated (Fig. 5). In this Figure, each successive point in
the line includes history from one additional Framingham study exam. As
more history is incorporated (by summing variable-years), some vari-
ables’ correlation with survival increases consistently and roughly linearly,
suggesting that these variables are indeed cumulative. Figure 5 shows
these traces with exams 16 and 20 as the focal exams. (These exams
were conducted when the participants were 59–69 and 67–77 years
old, respectively.) For focal exam 16, diastolic blood pressure exhibits a
consistent increase in mortality-prediction with each additional unit of
history for both men and women. In contrast, for focal exam 20,
diastolic blood pressure does not seem to accumulate predictivity from
history, while blood glucose does. We have also excluded the effects of
hypertension treatment in Figs 5 and 6. This caused the size of the
observed effects to decrease marginally without creating any substantial
differences from the same analysis of data uncontrolled for hypertension
treatment (data not shown). We believe that this steady increase in
mortality-predictive capacity with additional historical data is the
hallmark of a variable that affects health through cumulative exposure.
The switch in which variables predict future risk at different ages
between exams 16 and 20 is consistent with our earlier analysis, and
much other work (Albala et al., 1996) demonstrating the dramatic
change in risk factors with age (Fig. 3).
To further examine these trends, we focused on diastolic blood
pressure, BMI and blood glucose, which appear to be cumulative when
considered from the perspective of exams 16 and 20. For each variable,
Fig. 6 shows the utility of additional years of history when starting from
a range of focal exams, rather than just exams 16 and 20. In particular,
BMI seems to increase in mortality-predictive capacity as more history is
incorporated, regardless of the clinical exam from which we begin the
analysis. In contrast, diastolic blood pressure appears to stop showing
signs of cumulative risk after clinical exam 17, which corresponds to an
average age of 65.9 years. Blood glucose, however, seems to behave as
an accumulating variable for all exams after clinical exam 13, which
corresponds to an average age of 58.0 years. Again, this extends our
result from earlier: Not only do blood glucose and blood pressure seem
to be important for mortality-risk prediction at different age regimes
(ages 35–60 and 57–73, respectively), their predictive capability within
their regimes is cumulative (ages 35–65, and 58–87, respectively); that is,
blood glucose and blood pressure appear to primarily predict mortality
through accumulated lifetime exposure.
Discussion
We surveyed the amount of variation in all-cause mortality that could be
predicted from physiology at early- to mid-adulthood, finding a modest
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Fig. 3 The individual variables’ ability to
predict survival changes over time. Blood
pressure, BMI, and weight are predictive of
mortality primarily from ages 35 to 60 and
while blood glucose is most predictive from
ages 57 to 73. Also, note that BMI, all three
measures of blood pressure, and weight all
decrease in predictivity as the cohort ages,
but blood glucose’s ability to predict
survival increases in middle age before
declining again.
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but nontrivial effect: 9.7% of variation in mortality at ages 28–38 can be
predicted using the common physiological measurements of height,
weight, BMI, blood glucose level, and systolic and diastolic blood
pressure. In addition, we have shown that our results are generally valid
for both men and women. Although there are several quantitative
differences in the magnitudes of effects and their precise timing, our
overarching conclusions apply to both genders.
Further, the amount of predictable mortality generally decreases as a
cohort ages and the least healthy individuals die off. This result is
consistent with survivorship bias: as the unhealthy individuals die off, the
surviving cohort becomes more homogeneous. As a result, the surviving
cohort will have less predictable variation in survival; that is, a greater
proportion of the variation will be random and not predictable.
Specifically, Fig. 3 shows that the ability of blood pressure (diastolic,
systolic, and pulse pressure), BMI, and weight to predict variation in
survival is high in early- to mid-adulthood, and gradually decreases up to
roughly age 60. Although there is some fluctuation in this trend, likely
the result of measurement noise, the overall direction for most variables
is clear. Blood glucose’s predictivity presents an interesting exception.
While essentially all other variables are decreasing in predictive capacity
(up to age 60), blood glucose’s predictive ability seems to sharply
increase from age 57, peaking around the age of 70. The fact that blood
pressure, BMI, and weight are predictive of mortality primarily from ages
35 to 60 and while blood glucose is most predictive from ages 57 to 73
suggests a fundamental difference between their contributions to all-
cause mortality.
In parallel, Fig. 6 demonstrates that harm mediated by hypertension
and obesity accumulates from ages 35 to 65, while mortality risk from
blood glucose accumulates from ages 58 to 87. In conjunction with the
results from Fig. 3 discussed above, these results suggest certain ‘critical
periods’ (Dietz, 1994) for damage accumulation and mortality predic-
tivity. These ‘critical periods’ vary between different physiological
parameters, but seem to represent times of damage accumulation and
high mortality predictivity for each parameter. Again, all-cause mortality
risk before age 70 seems is best predicted using blood pressure and BMI,
while mortality during the age regime from age 60 and through age 80
is associated with blood glucose. While the confounding effects of
changing societal habits over the years need to be taken into account,
this type of analysis promises to yield important insights into the
evolution of health and accumulated mortality risk over the course of the
aging process.
The simplistic explanation for these observed ‘critical periods’ is that
the changing predictive ability of blood glucose and other measurements
is entirely due to the aging process: In general, perhaps blood pressure
becomes a less important predictor with increasing age while the
predictive value of blood glucose increases. This interpretation, however,
is confounded by the changing life habits of the American population
over recent history. Shifts in diet and lifestyle have steadily increased the
contribution of diabetes mellitus to morbidity and mortality over the past
half-century, and advances in hypertension treatment have altered the
physiological interpretation of blood pressure measurements. Disentan-
gling these effects calls for additional analysis of both the Framingham
data as well as other cohorts.
In addition to surveying mortality predictivity in the single-time-point
context, we investigated trends in variables over time. Rates of change
for height, weight, BMI, blood glucose level, and systolic and diastolic
blood pressure were utterly unpredictive of future mortality, despite
several different approaches to estimating these rates of change.
However, in many cases the measured variables’ accumulated history
yielded substantially higher correlations in comparison with the single-
time-point context.
Specifically, the ability of diastolic blood pressure and BMI to predict
all-cause mortality risk increases steadily and roughly linearly as more
historical information is included for individuals below the age of 67. For
blood glucose, this effect is observed most prominently from the age 58
onward. In conjunction with our result that indicates that blood glucose
is mortality-predictive at later ages than blood pressure and BMI, these
‘accumulating regimes’ indicate that these variables’ effects on mortality
are cumulative.
This is consistent with the current understanding of the harms
mediated by obesity, high blood glucose, and high blood pressure. While
the precise mechanisms by which high blood pressure is pathological are
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Fig. 4 Hypotheses for the relationship between health (risk of mortality) and trends in physiological measurements. The potential scenarios considered are as follows: (left)
the derivative (‘rate of change’) of a measurement is the most relevant quantity for predicting mortality; (center) the current value of the measured parameter is
most predictive of mortality; (right) the integral (‘accumulated exposure’) is most predictive of mortality. In each panel, a blue line represents a ‘healthy’ time course, while a
purple line represents a more ‘unhealthy’ time course at higher risk for mortality. In the left panel, the precise values of the measurements over time are not important,
but their stability over time is. Thus, a trajectory in the midst of a sharp decline may be a risk factor, while a more stable trajectory is lower risk. The middle panel
illustrates the case in which a parameter value directly relates to underlying risk, so the current value of that parameter is most useful as a quantitative risk factor. Finally, the
right panel shows the case when an individual’s accumulated exposure is the relevant risk factor. Here, the total historical exposure (area under the curve) is more predictive
of mortality than the measure’s current value or rate of change; as such, in this example, the trajectory with the larger shaded area underneath is the more at-risk.
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still a subject of active research, the consensus so far is that the
hemodynamic forces of hypertension initiate a signal which is trans-
duced by endothelial cells, initiating various pathways involving ion
channels, growth factors, extracellular matrix interactions, and various
other molecular components (Luft et al., 1999). The end result of these
effects is generally a combination of vascular remodeling – blood vessels
becoming less pliable, weaker, narrower – and specific organ damage,
commonly in kidneys. Overall, it is generally agreed that the harmful
effects of hypertension occur gradually over time. Similar lines of
evidence suggest that pathologies from high blood glucose and obesity
occur gradually as well (Kahn et al., 2006).
Thus, it is not merely having high blood pressure, high blood glucose,
or being overweight that instantaneously puts one at risk for the various
associated pathologies. Rather, it is the sustained level of increased stress
on one’s organ systems that causes a gradual accumulation of damage.
This suggests that many current preventative medicine guidelines, which
focus on cardiovascular risk factors in older patients, may be failing to
fully capture the lasting dangers of an unhealthy lifestyle, especially for
younger individuals. In addition, while the concept of additional risk from
sustained lifetime exposure may be intuitively understood by physicians,
this study quantitatively highlights the magnitude of the effect, and
suggests a straightforward way to estimate risk from accumulated
exposure: simply summing historical physiological measurements. Fur-
ther, some recent work on functional impairment during the aging
process, as measured by frailty indices (Kulminski et al., 2007; Mitnitski
et al., 2013), may be evidence of downstream effects of accumulated
physiological damage.
With the advent of electronic medical records and ever-increasing
computing power, it is becoming commonplace to have access to
patients’ previous physiological measurements. By exploiting longitudinal
information in novel ways, we have shown that the predictive capacity of
many well-studied risk factors can be greatly increased. Further, these
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Fig. 5 A plot of how the mortality-predictive ability of single variables changes as more history is incorporated into an accumulated risk score at ‘focal exams’ 16 and 20.
Accumulating variables are identified by a steady increase in mortality-prediction with each additional unit of history. At exam 16, diastolic blood pressure exhibits a
consistent increase in mortality-prediction with each additional unit of history for both men and women, although the effect is smaller in size for men. In contrast, at exam
20, blood glucose accumulates predictivity with additional history for approximately 15 years, corresponding to ages 57–73. BMI, on the other hand, behaves as an
accumulating variable for women at focal exams 16 and 20, but is relatively unpredictive of mortality for men at these exams.
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statistical improvements can also drive new biomedical insights and
provide avenues for testing those hypotheses. Much previous work has
demonstrated the utility of physiological history for understanding the
processes that drive aging and the relationship between disease risk and
specific physiological measurements (Yashin et al., 2006, 2007; Arbeev
et al., 2011). Our results add to this understanding by demonstrating
clearly that early-life physiology informs late-life survival and that
cumulative historical exposure can be a useful variable to track in
addition to the present state of an individual’s physiology. Incorporating
early-life data (where available) and recent history into existing quan-
titative models may further improve our understanding of how and why
mortality risk increases with aging.
Experimental procedures
Data collection
The design of the Framingham Heart Study has been previously
described (Kannel et al., 1979; Collins et al., 1990). For our present
study, subjects in the original cohort who were ages 28 to 38 at the first
examination (1948–1953, 1451/5079 subjects) were eligible. We
excluded participants that were lost to follow-up (defined by lacking
both a known date of death and having no recorded data from clinical
exam 28) and those who were missing sufficient data for any of the six
physiological measures we studied (systolic blood pressure, diastolic
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Fig. 6 The accumulation of predictivity using additional years of history, starting at different exams. Each single time trace shown here is analogous to a single time trace in
Fig. 5. Each panel illustrates how additional years of historical data improve risk prediction for a different physiological variable. Unlike Fig. 5, which presents these
results from exams 16 and 20, here a range of ‘focal exams’ are shown. Each trace represents the change in mortality predictivity as additional years of history are
incorporated into the mortality prediction from a given starting point (‘focal exam’). For example, the yellow traces show how the predictive ability of a given measure at
exam 26 can be increased by adding additional historical data. Each particular point on a yellow trace then represents the gain in predictive ability when data area (as
illustrated in the right panel of Fig. 4) is added from exam 26 back to that particular point in time. As in Fig. 5, the hallmark of an accumulating variable is a steady increase
of predictivity with the incorporation of additional history. Note that BMI seems to accumulate predictivity as more history is incorporated, regardless of the focal exam from
which the analysis is begun. In contrast, diastolic blood pressure and blood glucose only accumulate predictivity in limited regimes. Diastolic blood pressure and blood
glucose accumulate risk from exams 1 to 14 and 13 to 20, respectively, which correspond to average ages of 35–60 and 57–73 years.
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blood pressure, blood glucose, height, weight, BMI). After applying our
criteria, 91 individuals were excluded on the basis of incomplete follow-
up and 10 individuals were excluded on the basis of insufficient data. We
then manually removed a single outlier individual, who had a systolic
blood pressure of 250 mm Hg at the first clinical exam (an extraordi-
narily pathological reading, approximately 8.8 standard deviations from
the mean) and died approximately 3 months later. We thus obtained a
cohort of 1349 participants who remained eligible for this study. In
Table 2, we see that the differences between our chosen cohort and
individuals excluded for lack of follow-up or insufficient data are
minimal, and are unlikely to cause significant bias in our results. By
selecting a birth decade cohort, we hope to minimize the confounding
effects of age, as all participants in our study are similar in age.
Statistics
Statistics (Pearson correlation coefficient, multiple regression weights,
partial correlations) were computed using the Python programming
language and associated packages.
Construction of clinical risk scores
It should be noted that although we made every effort to reconstruct the
Framingham and Pooled Cohort Equations risk scores as completely as
possible, the smoking and high-density lipoprotein cholesterol terms had
to be excluded due to the lack of consistent longitudinal measurement in
the Framingham Heart Study. For example, early blood cholesterol
measurements did not distinguish between high-, low-, and very low-
density lipoproteins. The data from smoking questionnaires also varied
among clinical exams, and were difficult to interpret consistently for all
longitudinal time points.
Blood pressure treatment
To minimize the confounding effects of blood pressure treatment in
Figs 5 and 6, we adjusted individuals’ blood pressure measurements to
reflect our best estimates of their untreated blood pressure. We achieved
this by adding the average effect of blood pressure treatment to all
individuals. Our results computed with controlled blood pressure were
not substantially different from those from the same analysis on
uncontrolled blood pressure (data not shown).
Pulse pressure
Pulse pressure, a derived variable defined as the difference between an
individual’s systolic anddiastolic bloodpressures,was includedas a seventh
variable in our analysis from Fig. 3 onward. We excluded pulse pressure
from Figs 1 and 2, which employedmultiple linear regression, because it is
linearly dependent on systolic and diastolic blood pressure and would not
havemade anymeaningful contribution to the derived composite variable.
Exam weighting in history accumulation
To adjust for unequal timing of clinical exams, we assumed that at any
given point in time, each patient has the samemeasurement as the closest
clinical exam. For example, if a patient has a measured systolic blood
pressure (in mm Hg) of 120 in 1960, 130 in 1966, and 140 in 1976, our
analysis would use this adjustment to assign blood pressures of 120 for
1960–1963, 130 for 1964–1971, and 140 for 1972–1976. Further, to
avoid artificially diminishing the impact of the first and last available time
points, we pad the first and last exams with half of the average interexam
period. In the given example, we would actually assign blood pressures of
120 for 1956–1963, 130 for 1964–1971, and 140 for 1972–1980.
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Table 2 Comparison of the selected vs. excluded Framingham Heart Study (FHS) participants
Average at Exam 01,
selected males
Average at Exam 01,
excluded males
P-value
(t-test),
males
Average at Exam 01,
selected females
Average at Exam 01,
excluded females
P-value
(t-test),
females
Blood glucose 79.1  18.65 mg dL1 77.1  13.11 mg dL1 0.57 78.3  12.86 mg dL1 76.8  10.42 mg dL1 0.39
Body mass index 25.6  3.71 kg m2 24.0  3.0 kg m2 0.02 23.8  4.28 kg m2 22.6  4.16 kg m2 0.03
Diastolic blood pressure 82.7  9.77 mm Hg 83.5  13.38 mm Hg 0.69 77.4  8.56 mm Hg 76.0  7.8 mm Hg 0.2
Systolic blood pressure 131.1  14.04 mm Hg 133.1  24.38 mm Hg 0.47 121.9  12.59 mm Hg 119.4  11.7 mm Hg 0.11
Height 68.4  2.74 inches 68.3  2.07 inches 0.82 63.1  2.34 inches 63.3  2.63 inches 0.6
Weight 172.58  26.24 pounds 161.83  21.31 pounds 0.03 137.34  23.78 pounds 132.0  23.3 pounds 0.07
Age 34.5  2.16 years 33.9  2.13 years 0.18 34.5  2.19 years 34.0  2.2 years 0.08
Number of participants 631 30 718 72
All parameter mean values are within a single standard deviation, suggesting that our exclusion criteria did not introduce any obvious bias. The only statistically significant
differences (at a P = 0.05 level) between included and excluded cohorts are in BMI and weight. However, even for BMI and weight, the excluded individuals’ mean values are
still within a standard deviation of those of the included cohort. Further, relatively few individuals were excluded in relation to those who remained in the cohort, so we
believe the risk of bias from our exclusion criteria to be minimal.
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Fig. S1. For men in early-to-mid adulthood (participants aged 28–38), 9.3%
of variation in future lifespan can be predicted from a weighted combination
of systolic and diastolic blood pressure, blood glucose, height, weight, and
body mass index.
Fig. S2. For women in early-to-mid adulthood (participants aged 28–38),
6.6% of variation in future lifespan can be predicted from a weighted
combination of systolic and diastolic blood pressure, blood glucose, height,
weight, and body mass index.
Fig. S3. The individual variables’ ability to predict survival in a single-time
point context, stratified by gender.
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